Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL28833029 | 0.85 | SLC7A5 (0.64) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Leucine SCHEMBL9068238 | 0.83 | SLC7A5 (0.62) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Benzophenone SCHEMBL29159318 | 0.83 | SLC7A5 (0.62) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Benzoic Acid SCHEMBL21385347 | 0.81 | CA2 (0.61) | SLC7A5CA2CA4SLC1A3SLC1A2 | |
| Naphthalene SCHEMBL8050416 | 0.81 | SLC7A5 (0.69) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Naphthalene SCHEMBL8050413 | 0.81 | SLC7A5 (0.69) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Leucine SCHEMBL29269093 | 0.80 | SLC7A5 (0.82) | SLC7A5RNPEPSLC1A3SLC1A2SLC1A1 | |
| Leucine SCHEMBL21141614 | 0.80 | SLC7A5 (0.67) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Leucine SCHEMBL4551207 | 0.80 | SLC7A5 (0.67) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Anthraquinone SCHEMBL27983864 | 0.78 | SLC7A5 (0.64) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829567-A1 | CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS | With Great Power, LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020023800-A1 | CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS | WITH GREAT POWER, LLC (US) | 2020-01-30 | — | — | WO | disclosed |